The efficacy of chimeric vaccines constructed with PEP-1 and Ii-Key linking to a hybrid epitope from heterologous viruses

详细信息    查看全文

• 作者：Xue-lan Liu^a ; ^{liuxuelan203@163.com" class="auth_mail" title="E-mail the corresponding author} ; Wen-jie Shan^a ; Shan-shan Xu^a ; Jin-jing Zhang^a ; Fa-zhi Xu^a ; Sheng-lin Xia^b ; Yin Dai^c ; ^{daiyin2020@163.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Ii-Key ; PEP-1 ; Heterologous epitope-peptide ; The vehicle effect ; Vaccine
• 刊名：Biologicals
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：43
• 期：5
• 页码：377-382
• 全文大小：863 K

文摘

The heterologous epitope-peptide from different viruses may represent an attractive candidate vaccine. In order to evaluate the role of cell-permeable peptide (PEP-1) and Ii-Key moiety from the invariant chain (Ii) of MHC on the heterologous peptide chimeras, we linked the two vehicles to hybrid epitopes on the VP2 protein (aa197–209) of the infectious bursal disease virus and HN protein (aa345–353) of the Newcastle disease virus. The chimeric vaccines were prepared and injected into mice. The immune effects were measured by indirect ELISA. The results showed that the vehicle(s) could significantly boost immune effects against the heterologous epitope peptide. The Ii-Key-only carrier induced more effective immunological responses, compared with the PEP-1 and Ii-Key hybrid vehicle. The carrier–peptide hybrids all showed strong colocalization with major histocompatibility complex (MHC) class II molecules compared with the epitope-peptide (weakly-binding) after co-transfection into 293T cells. Together, our results lay the groundwork for designing new hybrid vaccines based on Ii-Key and/or PEP-1 peptides.